Published in J Cardiovasc Pharmacol on January 01, 1987
A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flows. Clin Pharmacokinet (2015) 1.98
Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med (2011) 1.88
Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol (2007) 0.94
Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol (1990) 0.88
Dose-effect relationship of carvedilol in essential hypertension. An open study. Drugs (1988) 0.82
Non-β-blocking R-carvedilol enantiomer suppresses Ca2+ waves and stress-induced ventricular tachyarrhythmia without lowering heart rate or blood pressure. Biochem J (2015) 0.81
The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man. Br J Clin Pharmacol (1995) 0.80
Pharmacokinetics and pharmacodynamics of beta blockers in heart failure. Heart Fail Rev (2004) 0.79
Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study. Drugs (1988) 0.77
The safety of adding carvedilol to hypertensive patients inadequately treated with diuretics. Eur J Clin Pharmacol (1990) 0.76
Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches. Curr Pharm Des (2015) 0.76
The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. J Cardiovasc Pharmacol Ther (2010) 0.75
The use of carvedilol in elderly hypertensive patients. Eur J Clin Pharmacol (1990) 0.75
Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial. Eur J Clin Pharmacol (1990) 0.75
Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet (1989) 1.83
Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung (1988) 1.04
Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol (1986) 1.01
Seat belt use during pregnancy. West J Med (1992) 0.88
Stereoselective disposition of carvedilol in man after intravenous and oral administration of the racemic compound. Eur J Clin Pharmacol (1990) 0.88
Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker. Eur J Clin Pharmacol (1987) 0.88
Absolute bioavailability and bioequivalence of glibenclamide (Semi-Euglucon N). Int J Clin Pharmacol Ther Toxicol (1985) 0.88
High-performance liquid chromatographic method for the determination of carvedilol and its desmethyl metabolite in body fluids. J Chromatogr (1987) 0.85
Metabolism of carvedilol in man. Eur J Drug Metab Pharmacokinet (1992) 0.85
Kinetics of subcutaneous versus intravenous epoetin-beta in dogs, rats and mice. Pharmacology (1996) 0.83
Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator bm 06.022 in healthy volunteers. Thromb Haemost (1991) 0.82
Effect of 17beta-estradiol-bisphosphonate conjugates, potential bone-seeking estrogen pro-drugs, on 17beta-estradiol serum kinetics and bone mass in rats. Calcif Tissue Int (1996) 0.82
Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. Arzneimittelforschung (1988) 0.80
The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Exp Hematol (1991) 0.79
[Steady state kinetics of isosorbide-5-mononitrate in patients with coronary disease]. Med Welt (1981) 0.78
Clinical pharmacologic investigations with carvedilol, a new beta-blocker with direct vasodilator activity. Clin Pharmacol Ther (1986) 0.78
Haemodynamic abnormalities in hypertensive patients: a review of the influence of vasodilating drugs. J Int Med Res (1986) 0.77
Aminoguanidine inhibits albuminuria, but not the formation of advanced glycation end-products in skin collagen of diabetic rats. Diabetes Res Clin Pract (1999) 0.77
Pharmacokinetics of intravenous, intraperitoneal, and subcutaneous recombinant erythropoietin in patients on CAPD. A rationale for treatment. Contrib Nephrol (1989) 0.77
Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective first-pass extraction. J Cardiovasc Pharmacol (1992) 0.77
Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther (1991) 0.75
[Interaction of guar with glibenclamide and bezafibrate]. Beitr Infusionther Klin Ernahr (1983) 0.75
BM 12.434, a novel compound with vasodilating and beta-adrenoceptor-blocking activities. Clin Sci (Lond) (1981) 0.75
Pharmacodynamics, pharmacokinetics and metabolism of digitoxin and derivatives in cats. Naunyn Schmiedebergs Arch Pharmacol (1987) 0.75
Dose proportionality studies of novel thiazolidinedione derivatives as potent antidiabetic agents in mice. Arzneimittelforschung (1995) 0.75
Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. Arzneimittelforschung (1989) 0.75
A postulated mechanism of beta-sympathomimetic induction of rib and limb anomalies in rat fetuses. Teratology (1985) 0.75
Simultaneous automated determination of spironolactone metabolites in serum. J Pharm Sci (1977) 0.75
[The effect of orthostasis on the fructosamine value]. Wien Klin Wochenschr Suppl (1990) 0.75
Pharmacokinetics of some new oral blood glucose-lowering agents in dogs. Arzneimittelforschung (1995) 0.75
[Which factors determine the critical hematocrit as an indication for transfusion?]. Anaesthesist (1992) 0.75
[Report of experiences in the treatment of 16 cases of severe glycoside poisoning with digitalis antibody fragments (Fab)]. Z Kardiol (1984) 0.75
[Occupational medicine aspects of quinine production]. Zentralbl Arbeitsmed Arbeitsschutz Prophyl Ergonomie (1983) 0.75
Digital pulse plethysmography--a tool for investigating vasoactive substances. Methods Find Exp Clin Pharmacol (1985) 0.75
Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard). Int J Clin Pharmacol Ther Toxicol (1989) 0.75
Pharmacokinetics of picumast after administration of 14C-picumast dihydrochloride in dogs, rats, rabbits and monkeys. Arzneimittelforschung (1989) 0.75
[The critical hematocrit--an analysis]. Klin Anasthesiol Intensivther (1993) 0.75
[Nursing diabetic patients in the intensive care unit]. Krankenpfl J (1986) 0.75
Pharmacokinetics of picumast dihydrochloride in patients with liver cirrhosis. Arzneimittelforschung (1989) 0.75
[Conservative hemotherapy. Blood component therapy instead of whole blood transfusion and homologous blood saving methods]. Gynakologe (1995) 0.75
[Care of the diabetic patient in the intensive care unit]. Krankenpfl J (1987) 0.75
Animal experiments for estimating the radiation exposure of human subjects by radioactive drugs. Pharmacology (1988) 0.75
Metabolism of picumast after administration of picumast dihydrochloride and antiallergic activity of the main metabolites. Arzneimittelforschung (1989) 0.75
Enzymatic inhibition assay for fluorometric determination of allopurinol and oxipurinol in serum and urine. Arzneimittelforschung (1980) 0.75